Placeholder

Cefepime

CAS No:
88040-23-7 Categories: , ,
  • # LGM Pharma is a Cefepime CAS# 88040-23-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Cefepime
  • CAS #: 88040-23-7
  • Mode of Action:

    Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).

  • Pharmacodynamics:

    Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, and multiple drug resistant Streptococcus pneumoniae. A particular strength is its activity against Enterobacteriaceae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected

  • Metabolism:

    Hepatic. Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide).

  • Toxicity:

    Symptoms of overdose include seizures, encephalopathy, and neuromuscular excitability.

  • IUPAC: 1-{[(6R, 7R)-7-[(2Z)-2-(2-amino-1, 3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium
  • ATC: J01DE01
  • PubChem: 5479537
  • DrugBank: DB01413
  • Formula: C20H27N5O2
  • Molecular Mass: 480.561
  • Synonyms: Cefepima [spanish] Cefepimum [latin]
  • SMILES: CON=C(/C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1
  • AHFS Code: 08:12.06.16
  • InChl: HVFLCNVBZFFHBT-ZKDACBOMSA-N
  • General Reference:

    1. Chapman TM, Perry CM: Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med. 2003;2(1):75-107. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements
This website uses cookies. By using our site, you agree to our terms of service